Table 2.
Animal models used in past studies for evaluating abscopal effects.
| Mouse Strain | Age | Cancer Cell Line | Cell Type | Condition of Inoculation | RT Treatment (Total Dose, Fraction) | Endpoint | Note | Reference |
|---|---|---|---|---|---|---|---|---|
| C57BL/6 | 8 weeks | MC38 | mouse colon adenocarcinoma | right flank (MC38-CEA+), left frank (MC38-CEA-) | 8 Gy, 1 fr | tumor growth | Hodge et al., 2012 [104] | |
| C57BL/6 transgenic for human CEA | LL/2 | mouse lung adenocarcinoma, | right frank (LL2-CEA+), intravenously (LL2-CEA+) | 125I -brachytherapy 72 h exposure | pulmonary metastasis | lung metastasis model | ||
| C57BL/6, p53 null B6.129S2- Trp53 tm1Tyj | 4–6 weeks | LLC-LM, T241 | Lewis lung carcinoma, fibrosarcoma | midline dorsum | 24 Gy, 12 fr | tumor growth | irradiate non tumor site, leg | Camphausen et al., 2003 [105] |
| NCr nu/nu | BxPC-3 | pancreatic carcinoma cells | right and left flank | 10 Gy, 5 fr | tumor growth | Nude mouse | Blanquicett et al., 2005 [106] | |
| BALB/c, C57BL/6 | 6–8 weeks | TSA, MCA38 | mouse breast carcinoma, mouse colon carcinoma | right and left flank | 20 Gy, 1 fr 24 Gy, 3 fr 30 Gy, 5 fr |
tumor growth | Dewan et al., 2009 [107] | |
| BALB/c | 8 weeks | colon26 | mouse colon adenocarcinoma | left frank, after 3 weeks intra-splenic injection | 20 Gy, 10 fr | tumor growth (liver weight) | liver metastasis model | Yasuda et al., 2011 [108] |
| CD1 nu/nu | HCT116, A549 | human colorectal cancer, human lung adenocarcinoma | right and left flank | 10 Gy, 2 fr 20 Gy, 3 fr |
tumor growth | nude mouse | Strigari et al., 2014 [109] | |
| C57BL/6 | 4 weeks | none | 2 Gy, 1 fr 10 Gy, 1 fr 10 Gy, 5 fr |
norml tissue response | abscopal model without cancer | Aravindan et al., 2014 [110] | ||
| BALB/c | 4T1, TSA | mouse mammary carcinoma, mammaryadenocarcinoma | right and lefl flank | 30 Gy, 1fr | tumor growth | Vanpouille-Box et al., 2015 [55] | ||
| BALB/c | 6 weeks | K7M2 | mouse osteosarcoma | subcutaneous, right frontal lobes | 40 Gy (2Gy × 4, five consecutive days) | immune markers from peripheral brood | brain metastasis, irradiate for subcutaneous tumor | Xia et al., 2018 [111] |
| BALB/c, C57BL/6, athymic nude mice |
12 weeks | 67NR | breast cancer, Lewis lung carcinoma | right and left mammary fat pad | 10 Gy, 1 fr 15 Gy, 1 fr |
tumor growth, survival | compare the response of immunocompetent mouse with nude mouse | Markovsky et al., 2019 [112] |
| C57BL/6 | B16-F10, D4M | mouse melanoma | subcutaneous, right frontal lobes | 8 Gy, 4 fr | tumor growth | brain metastasis, irradiate for brain tumor | Pfannenstiel et al., 2018 [113] | |
| FVB (JAX) | Myc-CaP | mouse prostate cancer | frank and leg | 20 Gy, 2 fr | tumor growth, survival | Dudzinski et al., 2019 [114] | ||
| C57BL/6 | B16-F10 | mouse melanoma | right and left flank | 5 Gy, 1 fr 10 Gy, 1 fr 20 Gy, 1 fr |
tumor growth, survival | Vijayakumar et al., 2019 [115] | ||
| MXH10/Mo/Lpr | FM3A-Luc | mouse mamary carcinoma cells | lymph node | 8 Gy, 1 fr | tumor growth | lymph node metastasis model | Kikuchi et al., 2019 [116] | |
| C57BL/6 | MC38, B16F10 | mouse colon adenocarcinoma cell, mouse melanoma | upper and lower dorsum | 6 Gy, 3 fr 24 Gy, 3 fr |
tumor growth | Baba et al., 2020 [117] | ||
| BALB/c | 6 weeks | CT26.WT | mouses colon carcinoma | right and left flank | 12 Gy, 3 fr | tumor growth | Zhang et al., 2020 [118] |